129 related articles for article (PubMed ID: 27401967)
21. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
22. Internationally Comparable Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.
Symonds P; Moss E; Reed N
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):151-152. PubMed ID: 28043743
[No Abstract] [Full Text] [Related]
23. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT.
Davidson B; Gurusamy K; Corrigan N; Croft J; Ruddock S; Pullan A; Brown J; Twiddy M; Birtwistle J; Morris S; Woodward N; Bandula S; Hochhauser D; Prasad R; Olde Damink S; Coolson M; Laarhoven KV; de Wilt JH
Health Technol Assess; 2020 Apr; 24(21):1-38. PubMed ID: 32370822
[TBL] [Abstract][Full Text] [Related]
24. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
25. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Kehoe S; Hook J; Nankivell M; Jayson GC; Kitchener H; Lopes T; Luesley D; Perren T; Bannoo S; Mascarenhas M; Dobbs S; Essapen S; Twigg J; Herod J; McCluggage G; Parmar M; Swart AM
Lancet; 2015 Jul; 386(9990):249-57. PubMed ID: 26002111
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group.
Alberts DS; Jiang C; Liu PY; Wilczynski S; Markman M; Rothenberg ML
Int J Gynecol Cancer; 2004; 14(2):224-8. PubMed ID: 15086720
[TBL] [Abstract][Full Text] [Related]
27. Correlation of progression-free and post-progression survival with overall survival in phase III trials of first-line chemotherapy for advanced epithelial ovarian cancer.
Shimokawa M; Ohki M; Kaku T
Eur J Gynaecol Oncol; 2015; 36(4):370-5. PubMed ID: 26390685
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
29. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract][Full Text] [Related]
30. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial).
Vaidya JS; Wenz F; Bulsara M; Tobias JS; Joseph DJ; Saunders C; Brew-Graves C; Potyka I; Morris S; Vaidya HJ; Williams NR; Baum M
Health Technol Assess; 2016 Sep; 20(73):1-188. PubMed ID: 27689969
[TBL] [Abstract][Full Text] [Related]
31. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
32. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
Matulonis UA; Oza AM; Ho TW; Ledermann JA
Cancer; 2015 Jun; 121(11):1737-46. PubMed ID: 25336142
[TBL] [Abstract][Full Text] [Related]
33. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
34. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
35. Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia.
Piszczan S; Desalegn D; Petros H; Gurmu M; Kroeber ES; Addissie A; Mikolajczyk R; Ghebre RG; Mathewos A; Thomssen C; Jemal A; Kantelhardt EJ
Oncologist; 2019 Jun; 24(6):e303-e311. PubMed ID: 31023861
[TBL] [Abstract][Full Text] [Related]
36. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
[TBL] [Abstract][Full Text] [Related]
37. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
38. Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study.
Menon U; Gentry-Maharaj A; Ryan A; Sharma A; Burnell M; Hallett R; Lewis S; Lopez A; Godfrey K; Oram D; Herod J; Williamson K; Seif M; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso N; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Skates S; Parmar M; Jacobs I
BMJ; 2008 Nov; 337():a2079. PubMed ID: 19008269
[TBL] [Abstract][Full Text] [Related]
39. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience.
Königsrainer I; Horvath P; Struller F; Grischke EM; Wallwiener D; Königsrainer A; Beckert S
Langenbecks Arch Surg; 2014 Jun; 399(5):589-94. PubMed ID: 24817542
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
